Thyrocare Technologies Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹196Cr
- +18.1% YoY
- −9.7% QoQ
- Net profit
- ₹28Cr
- +47.4% YoY
- −41.7% QoQ
- Margin
- 30%
- +5 pp YoY
- −3 pp QoQ
Guidance rank: #16 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
Long-term sustainable growth is expected to be in the mid-teens range (12%–15%) for the franchise business. Organic growth of 15-16% over the next 2 years is achievable but will come at a cost; margins expected to remain stable, not improve significantly.
From Thyrocare Technologies Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Long-term sustainable growth is expected to be in the mid-teens range (12%–15%) for the franchise business.
- The partnerships business is anticipated to grow about 1.5 times faster than the franchise business, contributing to consolidated mid-teens growth.
- The company aims to maintain growth above market rates by strategic investments in franchisee network expansion and specialty offerings.
- Specialty segments like allergies and genomics are key areas of investment for future growth and market expansion.
- International business (e.g., Tanzania) is growing rapidly, doubling annually, though it remains a small part currently.
2 more points from Thyrocare Technologies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company plans a field expansion with 40 new field personnel expected in the next financial year.
- There are ongoing investments in specialty offerings, including setting up specialty labs and expanding the internal sales and doctor network (currently 80 doctors on staff).
- Capex so far this financial year is approximately INR 20-30 crores, excluding ROU (Right of Use) asset capitalization.
- ROU asset capitalization related to reagent rental machines increased to around INR 22-23 crores this year from INR 13 crores last year.
- Strategy on capex remains unchanged: buy equipment where cost-effective and use reagent rental models where advantageous, e.g., biochemistry on reagent rental, immunoassay machines bought.
2 more points from Thyrocare Technologies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Thyrocare Technologies Ltd said on order book & pipeline — free account, 30 seconds.
Thyrocare Technologies Ltd — Quarterly revenue & net profit
Thyrocare Technologies Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 196 | 166 | +18.1% | 217 | -9.7% |
| Operating profit (EBITDA) | 58 | 42 | +38.1% | 71 | -18.3% |
| Operating margin | 30% | 25% | +5 pp | 33% | -3 pp |
| Profit before tax | 35 | 28 | +25% | 63 | -44.4% |
| Net profit (PAT) | 28 | 19 | +47.4% | 48 | -41.7% |
| EPS (₹) | 1.82 | 1.20 | +51.7% | 3.02 | -39.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹271 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Thyrocare Technologies's management said in earlier quarters
Others in Healthcare Services this season
- Vijaya Diagnostic Centre (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —
- Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Chandan Healthca (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Childrens Medicare (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Thyrocare Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Thyrocare Technologies Ltd Q3 FY26 results?
Long-term sustainable growth is expected to be in the mid-teens range (12%–15%) for the franchise business. Organic growth of 15-16% over the next 2 years is achievable but will come at a cost; margins expected to remain stable, not improve significantly.
What is Thyrocare Technologies Ltd share price analysis?
Thyrocare Technologies Ltd currently shows a neutral. The stock trades at a P/E of 52.8 with a market cap of ₹9,550 Cr. Investors should review the full earnings analysis for detailed insights.
Is Thyrocare Technologies Ltd planning capital expenditure?
The company plans a field expansion with 40 new field personnel expected in the next financial year.
Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
